Prednisone undergoes extensive first-pass metabolism, primarily in the liver. This process converts prednisone to its active metabolite, prednisolone. Approximately 80-90% of an oral prednisone dose is metabolized to prednisolone. This conversion is facilitated by the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).
The rate of this conversion varies significantly between individuals. Factors influencing this conversion include genetic polymorphisms in 11β-HSD1, liver function, and potential drug interactions. For example, ketoconazole inhibits 11β-HSD1, reducing prednisolone formation. Conversely, rifampin can induce 11β-HSD1, potentially increasing prednisolone levels.
Prednisolone is the primary pharmacologically active glucocorticoid responsible for the therapeutic effects of prednisone. Therefore, understanding this metabolic pathway is crucial for effective dosing and managing potential adverse effects. Clinicians should consider individual patient factors, particularly liver health and concurrent medications, when prescribing prednisone.
Note: The pharmacokinetics of prednisone and prednisolone are complex. Individual responses vary. Always consult a healthcare professional for proper diagnosis and treatment.
Key takeaway: Prednisone’s therapeutic efficacy relies heavily on its conversion to prednisolone. Variations in this metabolic step necessitate careful consideration during treatment.
